PRISMAP+ - Furthering the European Medical Radionuclide Programme

PRISMAP + - furthering the European Medical Radionuclide Programme, federates a consortium of 23 beneficiary or associate institutes. Nuclear medicine and research with novel radiopharmaceuticals is fast evolving with the 1st blockbuster treatment radiopharmaceutical Pluvicto® on the market last year. Based on recommendations from the Council of Europe to consolidate the European Radioisotope Valley Initiative programme and associated R&D for medical radionuclides, and therefore to extend the successful PRISMAP programme, PRISMAP + is submitted to this call to coordinate the access for biomedical researchers in Europe to a consortium of leading facilities. It extends the supply chain in geographical and scope from the maturing PRISMAP consortium, including intense neutron sources, proton and alpha accelerators, mass separation, including 2 new operating accelerators, and hosting researchers in our biomedical hubs. Planned for 2026-2029, the access platform radionuclides.eu will display relevant evolving information, manage the access in the project selection and publish relevant information as projects outcomes and dissemination become necessary. Accesses to services will furthermore be provided in our biomedical hubs, extended to larger geographical reach in Norway and Greece.